Jeroen P. H. van Wijk
Department of Vascular Medicine G02.405
University Medical Center
PO Box 85500
3508 GA
Netherlands
Name/email consistency: high
- Effects of rosiglitazone on postprandial leukocytes and cytokines in type 2 diabetes. van Wijk, J.P., Cabezas, M.C., Coll, B., Joven, J., Rabelink, T.J., de Koning, E.J. Atherosclerosis (2006)
- In vivo evidence of impaired peripheral fatty acid trapping in patients with human immunodeficiency virus-associated lipodystrophy. van Wijk, J.P., Cabezas, M.C., de Koning, E.J., Rabelink, T.J., van der Geest, R., Hoepelman, I.M. J. Clin. Endocrinol. Metab. (2005)
- Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes. van Wijk, J.P., de Koning, E.J., Castro Cabezas, M., Rabelink, T.J. Diabetes. Care (2005)
- Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. van Wijk, J.P., de Koning, E.J., Cabezas, M.C., op't Roodt, J., Joven, J., Rabelink, T.J., Hoepelman, A.I. Ann. Intern. Med. (2005)
- Normal ranges of non-fasting triglycerides in healthy Dutch males and females. van Wijk, J.P., van Oostrom, A.J., Castro Cabezas, M. Clin. Chim. Acta (2003)
